KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBIT Margin: 2016-2024

Historic EBIT Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Dec 2024 value amounting to 8.92%.

  • Amneal Pharmaceuticals' EBIT Margin fell 368.00% to 8.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 12.19%, marking a year-over-year increase of 519.00%. This contributed to the annual value of 8.92% for FY2024, which is 39.00% up from last year.
  • As of FY2024, Amneal Pharmaceuticals' EBIT Margin stood at 8.92%, which was up 4.51% from 8.54% recorded in FY2023.
  • In the past 5 years, Amneal Pharmaceuticals' EBIT Margin registered a high of 8.92% during FY2024, and its lowest value of -4.29% during FY2022.
  • Moreover, its 3-year median value for EBIT Margin was 8.54% (2023), whereas its average is 4.39%.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' EBIT Margin surged by 1,987bps in 2020, and later tumbled by 1,159bps in 2022.
  • Amneal Pharmaceuticals' EBIT Margin (Yearly) stood at 4.57% in 2020, then surged by 272bps to 7.29% in 2021, then tumbled by 1,159bps to -4.29% in 2022, then surged by 1,283bps to 8.54% in 2023, then spiked by 39bps to 8.92% in 2024.